An observational study in Diabetes Mellitus, Type 2 and Obesity, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-19.
Sponsored by Imperial College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Diabetes Mellitus, Type 2 by Imperial College London — 7 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Imperial College London.
Among the 19 studies in Diabetes Mellitus, Type 2 by Imperial College London, this one is one of 3 that started in 2018, is one of 5 observational ones, and was the 12th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 19 studies in Diabetes Mellitus, Type 2 by Imperial College London are open now, in 2 countries. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in Ireland
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18–70
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 210 is below the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 117 across the 14 interventional studies, 158 across the 5 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
4 of the studies in Diabetes Mellitus, Type 2 by Imperial College London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06782568Imperial College LondonAvoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics | 2026-12-31 |
| NCT04432025Imperial College LondonMedication Following Bariatric Surgery for Type 2 Diabetes Mellitus | 2027-04-01 |
| NCT07422532Imperial College LondonA Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing Haemodialysis | 2027-05-01 |
| NCT05404061Imperial College LondonThe Poor Responders Study | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Diabetes Mellitus, Type 2 by Imperial College London, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study investigating the influence of fat distribution, genetic susceptibility markers for type 2 diabetes (T2DM) and fat distribution, epigenetic and transcriptomic changes and gut hormone responses to a mixed meal on diabetes remission following bariatric surgery.
Up to 150 patients recruited to completion from Imperial Weight Centre. Up to 60 healthy volunteers
Bariatric surgery group
Inclusion Criteria:
Exclusion Criteria:
Healthy volunteers
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with type 2 diabetes undergoing Roux-en-Y gastric bypass surgery
Procedure: Roux-en-Y gastric bypass (RYGB)
Healthy volunteers with normal body mass index
Bariatric surgery
Diabetes remission (partial or complete)
Time frame: 1 year
Diabetes remission (complete)
Time frame: 1 year
Waist circumference, waist/hip ratio (cm)
Time frame: 1 year
Body mass index (kg/m2)
Time frame: 1 year
Weight loss
Time frame: 1 year
Change in visceral adipose tissue
Dual Energy Xray Absorptiometry measurement (DEXA)
Time frame: 1 year
Change in visceral adipose tissue
Magnetic resonance imaging (MRI) measurement
Time frame: 1 year
Change in ectopic fat
MRI measurement
Time frame: 1 year
Change in epigenetic data in tissues.
Time frame: 1 year
Changes in the transcriptome in tissues
Time frame: 1 year
Changes in gut hormone profiles
Time frame: 1 year
Histological scoring of specimens for Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis
Time frame: 1 year
Changes in gut microbiome
Time frame: 1 year
Plan to share: No
Started Oct 2018 (actual). Primary completion is estimated for Jan 2025, 75 months after the start.
Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 75 months is above that.
Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.